Catalyst Pharmaceuticals, Inc. (CPRX)
NASDAQ: CPRX · IEX Real-Time Price · USD
15.80
+0.03 (0.19%)
At close: Jul 2, 2024, 4:00 PM
15.63
-0.17 (-1.08%)
After-hours: Jul 2, 2024, 7:59 PM EDT
Catalyst Pharmaceuticals Revenue
Catalyst Pharmaceuticals had revenue of $411.35M in the twelve months ending March 31, 2024, with 60.38% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $98.51M with 15.40% year-over-year growth. In the year 2023, Catalyst Pharmaceuticals had annual revenue of $398.20M with 85.90% growth.
Revenue (ttm)
$411.35M
Revenue Growth
+60.38%
P/S Ratio
4.54
Revenue / Employee
$2,463,156
Employees
167
Market Cap
1.87B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 398.20M | 184.00M | 85.90% |
Dec 31, 2022 | 214.20M | 73.37M | 52.10% |
Dec 31, 2021 | 140.83M | 21.76M | 18.27% |
Dec 31, 2020 | 119.07M | 16.77M | 16.39% |
Dec 31, 2019 | 102.31M | 101.81M | 20,361.20% |
Dec 31, 2018 | 500.00K | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Dec 31, 2012 | 0 | - | - |
Dec 31, 2011 | 0 | - | - |
Dec 31, 2010 | 0 | - | - |
Dec 31, 2009 | 0 | - | - |
Dec 31, 2008 | 0 | - | - |
Dec 31, 2007 | 0 | - | - |
Dec 31, 2006 | 0 | - | - |
Dec 31, 2005 | 0 | - | - |
Dec 31, 2004 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BrightSpring Health Services | 9.37B |
AMN Healthcare Services | 3.48B |
LifeStance Health Group | 1.10B |
Amphastar Pharmaceuticals | 676.21M |
NovoCure | 525.66M |
LeMaitre Vascular | 199.89M |
Ardelyx | 159.11M |
Kymera Therapeutics | 79.41M |
CPRX News
- 4 weeks ago - Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE® - GlobeNewsWire
- 5 weeks ago - Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024 - GlobeNewsWire
- 7 weeks ago - Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May - GlobeNewsWire
- 2 months ago - Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024 - GlobeNewsWire
- 3 months ago - Jim Cramer recommends five small-cap health-care stocks - CNBC
- 3 months ago - Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day - GlobeNewsWire
- 3 months ago - Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium - GlobeNewsWire